Scientists Resurrect Ancient Cannabis Enzymes, Revealing How THC and CBD Evolved
Advertisement
For the first time, researchers have peered millions of years into the past to understand how the cannabis plant acquired its most famous chemical powers. A team at Wageningen University and Research in the Netherlands has reconstructed and resurrected ancient enzymes that once operated in the ancestors of modern cannabis, experimentally demonstrating how the plant evolved the ability to produce THC, CBD, and CBC — three of the most important cannabinoids known to science. The study, published in Plant Biotechnology Journal, not only solves a long-standing evolutionary mystery but also opens new doors for pharmaceutical manufacturing.
Key Takeaways
- The common ancestor of modern cannabinoid enzymes was a generalist that produced all three cannabinoids simultaneously before specializing through gene duplication over millions of years.
- Wageningen University researchers resurrected ancient cannabis enzymes using ancestral sequence reconstruction, demonstrating for the first time how THC, CBD, and CBC production evolved.
- The ancient enzymes are easier to produce in yeast and other microorganisms, potentially making biotech cannabinoid manufacturing more efficient.
Table of Contents
- Resurrecting Enzymes from Millions of Years Ago
- From Generalist to Specialist
- Implications for Biotechnology and Medicine
- What This Means for Cannabinoid Medicine
- The Bigger Picture: Understanding Cannabis at a Molecular Level
Resurrecting Enzymes from Millions of Years Ago
The research team, led by Robin van Velzen and collaborator Cloé Villard, used a technique called ancestral sequence reconstruction to travel backward through evolutionary time. The method works by analyzing DNA from modern cannabis plants and using computational models to infer what the plant's enzymes looked like at various points in its evolutionary history — in some cases, millions of years ago.
Once the team had computed the likely sequences of these ancient enzymes, they synthesized them in the laboratory and tested their function. What they discovered overturned a key assumption about how cannabinoid production evolved.
The prevailing theory had been that modern cannabinoid synthase enzymes — the molecular machinery responsible for producing THCA [Quick Definition: THC-acid — a non-psychoactive precursor that converts to THC when heated], CBDA, and CBCA (the acidic precursors to THC, CBD, and CBC) — each evolved independently to produce their specific compound. Instead, the Wageningen team found that the common ancestor of all three enzymes was a generalist: a single promiscuous enzyme capable of producing all three cannabinoids simultaneously.
From Generalist to Specialist
The evolutionary picture that emerged is elegant in its simplicity. Early in cannabis history, one ancestral enzyme produced a mix of THCA, CBDA, and CBCA at the same time. Over millions of years, the gene encoding this enzyme underwent duplications — creating extra copies that could mutate and evolve independently.
Through natural selection, each copy gradually specialized, becoming more efficient at producing one specific cannabinoid while losing the ability to make the others.
This process of gene duplication followed by functional specialization is a well-known mechanism in evolutionary biology, but the Wageningen study provides the first experimental evidence that it occurred in cannabis. The result is the trio of specialized enzymes we see in modern cannabis plants: THCA synthase, CBDA synthase, and CBCA synthase, each dedicated to producing a single cannabinoid.
Understanding this evolutionary pathway provides researchers with a molecular roadmap of how these enzymes changed over time, which amino acid substitutions drove specialization, and how the cannabis plant's chemistry became so complex.
Implications for Biotechnology and Medicine
The discovery has immediate practical applications. One of the most significant findings is that the reconstructed ancestral enzymes proved easier to produce in microorganisms, such as yeast cells, than their modern counterparts. This matters enormously because the cannabis industry is increasingly turning to biotechnological methods to produce cannabinoids — growing them in yeast fermentation tanks rather than in fields of cannabis plants.
Modern cannabinoid synthase enzymes are notoriously difficult to express in microbial production systems. They fold poorly, degrade quickly, and often produce low yields. The ancestral enzymes, being more robust and flexible, could solve these problems and make biotech cannabinoid production more efficient and cost-effective.
Van Velzen highlighted one particularly promising application: a reconstructed intermediate enzyme that produces CBC with high specificity. CBC, or cannabichromene, is a non-psychoactive cannabinoid with documented anti-inflammatory and analgesic properties, but it exists in relatively low concentrations in most modern cannabis strains. Van Velzen noted that introducing this enzyme into a cannabis plant could lead to innovative medicinal varieties rich in CBC, potentially creating new therapeutic options for patients.
What This Means for Cannabinoid Medicine
The study arrives at a time when the medical cannabis field is expanding rapidly. More than 70 cannabis-related studies have been published in 2026 alone, covering applications from pain relief and cancer treatment to brain injury recovery and sleep improvement. Yet the supply of specific cannabinoids for research and medicine remains a bottleneck.
CBC is a prime example. Despite its therapeutic promise, it has received far less attention than THC or CBD because cannabis plants produce it in such small quantities. If biotech companies can use ancestral or engineered enzymes to produce CBC at scale, it could accelerate clinical research and eventually lead to new treatments.
The same logic applies to rare cannabinoids beyond CBC. The evolutionary framework established by the Wageningen team provides a template for engineering enzymes that produce specific cannabinoids on demand, whether in yeast bioreactors or in genetically modified cannabis plants.
The Bigger Picture: Understanding Cannabis at a Molecular Level
Beyond its practical applications, the study deepens our fundamental understanding of why cannabis produces cannabinoids in the first place. The evolution of specialized enzymes suggests that producing distinct cannabinoids conferred survival advantages to the plant — potentially through pest resistance, UV protection, or other ecological functions that scientists are still working to fully understand.
For consumers, growers, and medical professionals, this research reinforces a message that the cannabis science community has been emphasizing: the plant's chemistry is far more complex and nuanced than the simple THC-versus-CBD dichotomy that dominates popular understanding. Cannabinoids like CBC, along with dozens of other compounds, play important roles in the overall therapeutic profile of cannabis.
As biotechnology and evolutionary biology continue to converge, studies like this one will likely become increasingly common — and increasingly consequential for the future of cannabis medicine.
Pull-Quote Suggestions:
"Over millions of years, the gene encoding this enzyme underwent duplications — creating extra copies that could mutate and evolve independently."
"For the first time, researchers have peered millions of years into the past to understand how the cannabis plant acquired its most famous chemical powers."
"The method works by analyzing DNA from modern cannabis plants and using computational models to infer what the plant's enzymes looked like at various points in its evolutionary history — in some cases, millions of years ago."
Why It Matters: Wageningen researchers resurrected million-year-old cannabis enzymes to reveal how THC, CBD, and CBC evolved — and unlocked new paths for biotech medicine.